Jinfeng Tang: Bringing Finance, Investment, and Life Sciences Innovation Together at TangGene
Building a successful biotechnology company requires more than breakthrough science. It also requires access to capital, strong operational leadership, strategic decision-making, and a clear understanding of how to build an emerging company.
Jinfeng Tang, Co-Founder and CEO of TangGene, brings those disciplines together through more than 20 years of experience spanning finance, risk management, startup investing, and early-stage company development.
Advancing Immunotherapies for Autoimmune Diseases
At TangGene, Jinfeng leads the company’s strategy, fundraising, and operations as the biotechnology company works to advance first-in-class immunotherapies for autoimmune diseases.
Developing innovative therapies requires companies to navigate complex challenges well beyond the laboratory—from securing investment and building the right leadership team to developing an organization capable of moving promising science forward.
Jinfeng’s background provides him with a particularly interesting perspective on that journey.
From Global Finance to Life Sciences Entrepreneurship
Before becoming an entrepreneur and investor, Jinfeng held senior positions at JPMorgan Chase, BlackRock, and Deutsche Bank, developing extensive experience in finance and risk management.
Today, he also serves as Managing Partner of Tang Capital, where he has invested in more than a dozen technology startups, including multiple life sciences companies.
Throughout his career, Jinfeng has worked closely with early-stage businesses in several capacities—as an investor, advisor, board member, and operating executive. That combination gives him insight into both sides of the table: what founders need to build companies and what investors look for when deciding where to commit capital.
Building the Next Generation of Life Sciences Companies
The intersection of biotechnology, entrepreneurship, and investment is becoming increasingly important as emerging life sciences companies work to translate innovative research into viable therapies and sustainable businesses.
Leaders such as Jinfeng demonstrate the value of combining scientific innovation with disciplined company building, financial strategy, and investment experience.
We look forward to hearing more about Jinfeng’s experience, the development of TangGene, and his perspective on building and financing emerging companies in today’s evolving life sciences and biotechnology ecosystem.
